ESPR Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$3.20median target· current $3.18 (+0.6%)6 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio0.00Forward 4.64
EPS (TTM)$0.000.0% YoY
Profit margin-1.8%HEALTHCARE
Market cap$819.5MSmall cap
Valuation
- Forward P/E
- 4.64
- PEG ratio
- -4.78
- P/B
- 98.42
- P/S (TTM)
- 1.96
- EV/EBITDA
- 11.52
Profitability & growth
- ROE (TTM)
- -260.8%
- Operating margin
- -8.2%
- Revenue growth YoY
- 23.2%
- Dividend yield
- 0.0%
- Beta
- 1.06
Last earnings
May 8, 2026 · Estimate $-0.04 · Reported $-0.10
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Esperion Therapeutics Inc
Company profileEsperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3891 RANCHERO DRIVE, ANN ARBOR, MI
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$819.5M
Shares outstanding$257.7M
52W high$4.18
52W low$1.13
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent